Entries by Maren Kühr

Boosting Startup Ecosystems

The Technologiepark Heidelberg has been shaping ­Heidelberg‘s startup ecosystem with 100,000 sqm of lab and office spaces, individual startup support, and top events for over 40 years – offering ideal ­conditions for established companys and startups in the fields of life sciences, biotech, industry tech, and AI.

Enhancing macromolecule drug discovery with CDD

The landscape of macromolecule drug discovery is evolving rapidly, with oligonucleotides and peptides leading the way in innovative therapeutic applications. CDD Vault, a leading scientific data management system, significantly improves the way researchers manage macromolecule data by introducing a dedicated Macromolecule mode that seamlessly integrates with modern workflows.

European biotechs navigating a new financing environment

After the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging long-term financing trends as well as the recent events in the US, which may also impact the biotech industry.

Trump’s win will affect the biotechnology sector

During the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?

The golden age of engineered therapeutic antibodies

Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.

New CEO appointed

Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.